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Abstract
Background: Granulomatous inflammation has been previously reported in association with
cancer. Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is a new
minimally invasive test for investigating mediastinal lymphadenopathy. The identification of
granulomatous inflammation by EBUS-TBNA and the clinical implications of such detection in a
series of patients with previously treated cancer and new mediastinal lymphadenopathy has not
previously been performed.
Methods: All 153 consecutive patients undergoing EBUS-TBNA in an academic cancer institution
for suspected cancer in the mediastinum (mediastinal lymphadenopathy by CT imaging) were
reviewed. Patients with non-caseating granuloma identified by EBUS-TBNA were included.
Results: EBUS-TBNA identified non-caseating granuloma in 17/153 (11%) patients. A subset of 8/
153 (5.2%) had sarcoid like lymphadenopathy mimicking cancer recurrence (5/5 PET positive).
Another 8/153 (5.2%) patients with new mediastinal lymphadenopathy and no prior history of
cancer had a clinical syndrome consistent with sarcoidosis. One other patient with a history of
breast cancer was diagnosed with non-tuberculous mycobacteria infection. No patient required
mediastinoscopy and there were no complications.
Conclusion: In an academic cancer institute, at least 5% of patients undergoing EBUS-TBNA have
sarcoid-like lymphadenopathy mimicking cancer recurrence. Further studies to define the precise
etiology, natural history and prognosis of this phenomenon are warranted.
Background
In patients with a history of cancer, the onset of mediasti-
nal adenopathy often heralds a recurrence of their malig-
nancy. However, not all mediastinal adenopathy is due to
cancer recurrence and lymph node sampling is warranted.
Endobronchial ultrasound transbronchial needle aspira-
tion (EBUS-TBNA) allows real time assessment and
biopsy of mediastinal lymph nodes and therefore often
obviates the need for mediastinoscopy [1,2]. The utility of
EBUS-TBNA in the mediastinal nodal staging of lung can-
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cer has been defined [3]. More recently, the ability of
EBUS-TBNA to identify granuloma in the work-up of
patients with mediastinal adenopathy secondary to sus-
pected sarcoidosis has been reported [4]. Since the begin-
ning of the last century, "local sarcoid reactions" and
"sarcoid like lymphadenopathy" with pulmonary and
mediastinal involvement have been described in patients
with cancer [5-7]. In this report, we describe a group of
patients in whom EBUS-TBNA detected granulomatous
inflammation in suspected cancer recurrence and examine
the clinical implications of such a finding.
Methods
Patients
We reviewed all EBUS-TBNA performed at our institution
from August 2005 to September 2006 for undiagnosed
mediastinal adenopathy. Patients referred for mediastinal
staging were specifically excluded from further analysis.
All other patients in whom EBUS-TBNA identified non-
caseating granulomatous inflammation were analyzed.
The diagnosis of sarcoidosis or sarcoid like lymphadenop-
athy was made if clinico-radiological findings were sup-
ported by histopathologic findings from EBUS-TBNA
along with appropriate exclusion of other granulomatous
diseases (a composite of clinical history, follow-up and
laboratory results including tissue staining for fungi and
acid fast bacilli (AFB), fungal and mycobacterial cultures
and serum fungal antibody titers).
Procedure
All of the EBUS -TBNA were performed by interventional
pulmonology attendings (n = 3) with or without super-
vised fellows. Under general anesthesia with ventilation
via a laryngeal mask airway, conventional flexible bron-
choscopy (model BF-T160 bronchoscope, Olympus,
Japan) was first performed to examine the tracheobron-
chial tree. Thereafter, EBUS-TBNA using a linear array
ultrasonic bronchscope (Olympus XBF-UC 160F) with
dedicated 22-gauge needle (NA-202C Olympus ltd.) was
performed with ultrasonic examination of mediastinal
and hilar lymph nodes in a systematic fashion and subse-
quent transbronchial needle aspiration [8]. All lymph
nodes greater than 5 mm in short axis diameter were sam-
pled. A minimum of two separate passes of the 22-gauge
needle into each node was performed. The aspirated
material was smeared onto glass slides and separately
labeled. Smears were air dried as well as fixed in Carnoy's
solution (6 parts EtOH (absolute or 95%) 3 parts chloro-
form 1 part glacial acetic acid). Additional material was
aspirated into RPMI (Sigma-Aldrich, St. Louis, MO) and
analyzed using cytospin or cellblocks. Air dried smears
were stained using Diff-Quik stain (American Scientific
Products; McGaw Park, IL) and fixed specimens were
stained with Papanicolaou staining and examined by an
on-site cytologist to ensure adequate cellular material in
the specimen. If adequate tissue was not identified by on
site cytology after five passes, no additional passes were
carried out at that station. Histologic core samples were
not obtained in any of the patients. Our institutional
review board approved this analysis.
Results
All 153 consecutive patients referred for EBUS-TBNA for
mediastinal lymphadenopathy identified by CT imaging
were included. No cancer history was identified in 38
(24.8%). We identified 17 patients (11%) in whom
EBUS-TBNA identified non-caseating granuloma without
any evidence of malignancy (Figure 1). Cytological analy-
sis of EBUS-TBNA samples did not identify granuloma-
tous inflammation and cancer in the same node or
different nodal stations during the same procedure in any
of the patients.
Granulomatous inflammation by EBUS-TBNA in patients 
with a prior history of cancer (n = 9)
A subset of nine patients (6%) had a prior history of can-
cer and is highlighted in Table 1. All had new mediastinal
Endobronchial ultrasound image depicting transbronchial  needle aspiration of a left hilar lymph node 11L (LN) overly- ing left interlobar artery (A) in a patient with history of  breast cancer and new hilar adenopathy Figure 1
Endobronchial ultrasound image depicting trans-
bronchial needle aspiration of a left hilar lymph node 
11L (LN) overlying left interlobar artery (A) in a 
patient with history of breast cancer and new hilar 
adenopathy.J
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Table 1: Clinical, radiographic and demographic features of nine patients with suspected cancer recurrence in whom endobronchial ultrasound transbronchial needle aspiration detected 
granulomatous inflammation.
Age Sex 
Race
Oncological History 
Remission (yrs since 
initial diagnosis)
Chemotherapy Lymph node Characteristics Granuloma at 
other sites
Microbiologic Studies* Treatment Follow-up (months)
Station [8] Size mm PET +ve Culture (n) Staining Serology
1
56F
C
Breast Cancer
Neadjuvant
Chemotherapy
Paclitaxel
Lapatinib
7
11R
14
7
-N o P N N M A C
Infection
Rifabutin
Ethambutol
Clarithromycin
Radiographical and clinical 
improvement on 
antimycobacterial therapy
2
28F
C
Melanoma
(2)
No 4R
7
7
13
- No N (1) N - None No symptoms (11)
3
49M
H
Hodgkin's
Lymphoma
Stage 1a
(8)
No 11R 14 Yes No N (2) N - None No symptoms
Node PET uptake and CT 
size reduced (6)
4
56F
AA
GI Stromal Tumor
(1)
Imatimib 4R 17 - TBBX** N (1) N - Inhaled
Fluticasone
Productive Cough
Progressive Pulmonary 
Infiltrates (12)
5
61F
C
NSCLC
T2N2M0
(1)
Carboplatin
Docetaxel
11R 9 Yes No N (1) N - Inhaled
Fluticasone
Chronic cough
Stable CT-PET (6)
6
63M
C
Melanoma
(4)
No 2R
7
10
11
Yes
Yes
Lymphocytic 
Meningitis**
N (3) N N Prednisone
For neurosarcoidosis
Neurological Symptoms
No pulmonary symptoms
Node PET uptake and CT 
size reduced (15)
7
66M
C
Multiple Myeloma
(3)
Melphalan
Thalidomide
Lenalidomide
11R 11 Yes EBBX**
TBBX
N (2) N N None No symptoms
Stable CT-PET (8)
8
68F
AA
Endometrial Cancer
(2)
Docetaxel
Carboplatin
Imatimib
7
11R
13
10
Yes
Yes
No** N (1) N - None No symptoms
Stable CT-PET
Intraabdominal cancer 
Recurrence (9)
9
77M
C
Colorectal Cancer
(3)
Cisplatin
Capecitabine
7 10 - No** N (2) N - None No symptoms
Stable CT (10)
* Fungal and mycobacterial cultures (bronchoalveolar lavage or bronchial wash or sputum), tissue staining for fungi and acid fast bacilli (AFB), and serum fungal antibody titers.
** Pulmonary parenchymal involvement on high resolution CT.
AA = African American, AFB = acid fast bacilli, BAL = bronchoalveolar lavage, C = Caucasian, CT = computed tomography, EBBX = endobronchial biopsy, EBUS = endobronchial ultrasound, F = female, GI = 
gastrointestinal, H = Hispanic, M = male, MAC = Mycobacterium avium intracellulare infection, N = negative, P = positive, PET = positron emission tomography, TBBX = transbronchial biopsy, Yrs = yearsJournal of Cardiothoracic Surgery 2008, 3:8 http://www.cardiothoracicsurgery.org/content/3/1/8
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lymphadenopathy suspicious for cancer recurrence and
EBUS-TBNA identified granulomatous inflammation
without any evidence of cancer. No patient had a prior
history of granulomatous disease or infection. A PET scan
had been performed in 5 patients prior to EBUS-TBNA
and the enlarged mediastinal lymph nodes were positive
in all. Upon review of prior cancer treatment, five of the
eight patients received chemotherapy, including imatinib,
and docetaxel in two patients each.
Non-tuberculous mycobacteria infection (Mycobacterium
avium intracellulare) was identified in one of the nine
patients with symptoms responding to antimycobacterial
treatment. Tissue staining for AFB organisms and fungi
and respiratory cultures (average 1.6 per patient) were
negative in all of the other eight patients. In all eight
patients, pathological review of all the tissue available at
the original time of cancer diagnosis did not reveal any
evidence of granulomatous inflammation. One patient
(patient 5) had evidence of mediastinal lympadenopathy
at the time of original cancer diagnosis, and a mediasti-
noscopy at the time was positive for cancer, but negative
for granuloma. However, the mediastinal adenopathy
regressed with therapy and restaging scans subsequently
revealed recurrent mediastinal lymphadenopathy requir-
ing repeat sampling (EBUS-TBNA) that revealed granulo-
matous inflammation.
Evidence for granulomatous inflammation at other sites
was also evaluated. Five patients had pulmonary paren-
chymal abnormalities consistent with sarcoid parenchy-
mal disease on high resolution CT scan. Two of these
patients had concomitant transbronchial lung biopsies
positive for granuloma.
Confirmatory medistinoscopy was not deemed necessary
for any of the patients and close radiographic follow up
was instituted. Upon follow-up for an average of 10
months (range 6–15 month), two patients developed pro-
gressive cough that responded to treatment with inhaled
fluticasone, while one other patient developed sympto-
matic lymphocytic meningitis consistent with neurosar-
coidosis and was treated with systemic steroids. All other
patients remained clinically and radiographically stable
except for one patient who developed an intraabdominal
recurrence of endometrial cancer. Interestingly however,
her mediastinal adenopathy remained unchanged.
Granulomatous inflammation by EBUS-TBNA in patients 
without a prior history of cancer (n = 8)
The other 8/17 patients had no prior cancer history, and
underwent EBUS-TBNA to rule out a malignant cause of
mediastinal lymphadenopathy. Granulomatous inflam-
mation was found in all by EBUS TBNA and all 8 were
ultimately diagnosed with systemic sarcoidosis on the
basis of a compatible clinical history, granulomatous
inflammation (by EBUS-TBNA and transbronchial lung
biopsy in 5 patients) and adequate exclusion of other
granulomatous diseases. There were no complications
related to the EBUS-TBNA procedure in any of the 17
patients.
Discussion
Consistent with the recently published study of the utility
of EBUS-TBNA in the diagnosis of sarcoidosis, we have
confirmed that EBUS-TBNA can identify granulomatous
disease in the mediastinum [4]. However, in an academic
cancer center, we identified a sub-group of patients with a
prior history of cancer with new mediastinal lymphaden-
opathy in whom EBUS-TBNA detected granulomatous
inflammation. These patients account for at least 5% of all
EBUS-TBNA performed at our institution. This may be an
underestimation as we only perform cytological examina-
tion of aspirated material routinely, without histologic
cores that are difficult to obtain with the currently availa-
ble 22 gauge needles. Furthermore, the false negative rate
for granulomatous inflammation was not investigated
with mediastinoscopy in our series.
Despite the fact that it has been recognized for over a cen-
tury that an association between granulomatous inflam-
mation and cancer exists, the cause of this relationship is
unknown [5-7]. Many hypotheses exist such as immuno-
logical dysfunction related to cancer and sarcoidosis, a
side effect of cancer therapy (although the phenomenon
has been described in cancer patients treated with surgery
alone [9]), and "antigenic shedding" from the tumor lead-
ing to granuloma formation [6,7]. In fact, there is no
agreement on what to name the phenomenon of medias-
tinal and hilar adenopathy secondary to granulomatous
inflammation in treated cancer patients (sarcoid like reac-
tion, sarcoid like lymphadenopathy, pulmonary and
mediastinal "sarcoidosis" or simply sarcoidosis). A
detailed analysis of these hypotheses and arguments is
beyond the limits of this report.
Prior reports have highlighted this phenomenon in many
different cancer types, although there seems to be an over
representation of patients with testicular germ cell tumors
[6,7,9-12]. Characteristics of the patients reported in this
manuscript such as a lack of prior history of granuloma-
tous disease or evidence of mediastinal adenopathy at the
time of cancer diagnosis, no ethnic association, varying
time between cancer and sarcoid diagnosis, adenopathy
distant to the primary site and varying course and
response to treatment are in keeping with prior reports
and differentiate this phenomenon from local sarcoid
reactions in draining lymph nodes which occur at the time
of primary cancer diagnosis [6,7,9-12]. Of note, two of the
patients we report were treated with imatinib and twoPublish with BioMed Central    and   every 
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with docetaxel which both have been associated with
interstitial lung disease, although neither with granulo-
matous inflammation [13,14].
The clinical relevance of this phenomenon, however, is
clear. Attributing radiographic findings such as mediasti-
nal lymphadenopathy without tissue confirmation as can-
cer recurrence can lead to unnecessary and toxic therapy
[11]. In all the patients reported in this manuscript, medi-
astinal lymphadenopathy met criteria for cancer recur-
rence by CT measurement and mediastinal
lymphadenopathy was considered FDG-avid in all five
patients who underwent PET imaging. In practice, new
onset hilar or mediastinal adenopathy is often attributed
to cancer recurrence without definitive tissue confirma-
tion. This is a situation fraught with peril as mediastinal
and hilar adenopathy may be secondary to other proc-
esses such as granulomatous inflammation and not can-
cer recurrence. However, in patients with a prior history of
cancer, mediastinoscopy, the 'gold standard' for mediasti-
nal lymph node sampling, may be difficult to perform
particularly with prior instrumentation or thoracic radia-
tion therapy. These patients are often frail with multiple
comorbidities that may preclude surgical options. With
the advent of EBUS-TBNA, a minimally invasive tool is
now available that allows for safe, accurate and repeated
hilar and mediastinal lymph node sampling. Despite the
small population studied, the fact that all patients diag-
nosed with granulomatous inflammation by EBUS -TBNA
remained clinically stable would seem to indicate that
EBUS-TBNA is able to reliably differentiate this sarcoid
like mediastinal granulomatous inflammation from can-
cer recurrence. Furthermore, only one patient had culture
evidence of a granulomatous infection, and all other
patients remained clinically stable without any antibiotic
therapy, again supporting a non-infectious etiology for
the adenopathy. Accordingly, if granulomatous inflam-
mation is identified by EBUS-TBNA in a patient with sus-
pected cancer recurrence, a reasonable clinical approach
would be to follow the patient radiographically without
additional invasive testing, unless radiographic progres-
sion was subsequently noted.
Conclusion
This study highlights the ability of EBUS-TBNA to detect
granulomatous inflammation in patients with suspected
cancer recurrence in mediastinal and hilar lymph nodes.
In this era of increasing cancer survivorship, and with the
improvements in sampling technology, this phenomenon
of granulomatous inflammation following cancer and
cancer therapy is likely to become a more commonly rec-
ognized entity and further study to define the precise eti-
ology, natural history and prognosis is warranted.
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